Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 451 to 500 of 797

TitleReference numberPublishedLast updated
Vandetanib for treating medullary thyroid cancerTA550
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)TA548
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Tofacitinib for moderately to severely active ulcerative colitisTA547
Padeliporfin for untreated localised prostate cancerTA546
Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaTA545
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Cabozantinib for untreated advanced renal cell carcinomaTA542
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Dinutuximab beta for treating neuroblastomaTA538
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Dupilumab for treating moderate to severe atopic dermatitisTA534
Ocrelizumab for treating relapsing–remitting multiple sclerosisTA533
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapyTA530
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's diseaseTA217
Guselkumab for treating moderate to severe plaque psoriasisTA521
Midostaurin for untreated acute myeloid leukaemiaTA523
Brentuximab vedotin for treating CD30-positive Hodgkin lymphomaTA524
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA525
Arsenic trioxide for treating acute promyelocytic leukaemiaTA526
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Tocilizumab for treating giant cell arteritisTA518
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Cabozantinib for treating medullary thyroid cancerTA516
Brodalumab for treating moderate to severe plaque psoriasisTA511
Tivozanib for treating advanced renal cell carcinomaTA512
Obinutuzumab for untreated advanced follicular lymphomaTA513
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the kneeTA508
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis CTA507
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal womenTA160
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal womenTA161
Pirfenidone for treating idiopathic pulmonary fibrosisTA504
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Ibrutinib for treating relapsed or refractory mantle cell lymphomaTA502
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Lenvatinib with everolimus for previously treated advanced renal cell carcinomaTA498
Glecaprevir–pibrentasvir for treating chronic hepatitis CTA499
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Golimumab for treating non-radiographic axial spondyloarthritisTA497
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495

Results per page

  1. 10
  2. 25
  3. 50
  4. All